NCT00393718已完成3 期
Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment
研究概览
简要总结
This trial is conducted in Japan. The trial aims for comparison of the effect on glycaemic control of liraglutide, compared to sulfonylurea (SU treatment), as assessed by HbA1c after 24 and 52 weeks in subjects with type 2 diabetes. Trial has a randomisation period of 24 weeks followed by a 28 week extension period, in total 52 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetes
- •Diet/exercise therapy with or without an oral anti-diabetic drug for at least eight weeks
- •HbA1c greater than or equal to 7.0% and less than 10.0%
- •BMI (Body Mass Index) less than 35 kg/m2
排除标准
- •Treatment with insulin within the last 12 weeks
- •Treatment with any drug that could interfere with the glucose level
- •Any serious medical condition
- •Females who are pregnant, have intention of becoming pregnant or are breastfeeding
研究组 & 干预措施
Glibenclamide
Active Comparator
Glibenclamide 1.25-2.5 mg + liraglutide placebo
干预措施: placebo (Drug)
Liraglutide
Experimental
Liraglutide 0.9 mg + glibenclamide placebo
干预措施: liraglutide (Drug)
Liraglutide
Experimental
Liraglutide 0.9 mg + glibenclamide placebo
干预措施: placebo (Drug)
Glibenclamide
Active Comparator
Glibenclamide 1.25-2.5 mg + liraglutide placebo
干预措施: glibenclamide (Drug)
结局指标
主要结局
Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment
时间窗: after 24 weeks of treatment
次要结局
- Glycosylated Haemoglobin A1c (HbA1c) After 52 Weeks of Treatment(after 52 weeks of treatment)
- Fasting Plasma Glucose After 24 Weeks of Treatment(after 24 weeks of treatment)
- Fasting Plasma Glucose After 52 Weeks of Treatment(after 52 weeks of treatment)
- Postprandial Glucose AUC After 24 Weeks of Treatment(after 24 weeks of treatment)
- Postprandial Glucose AUC After 52 Weeks of Treatment(after 52 weeks of treatment)
- Mean PG in 7-point Plasma Glucose Profile After 24 Weeks of Treatment(after 24 weeks of treatment)
- Mean PG in 7-point Plasma Glucose Profile After 52 Weeks of Treatment(after 52 weeks of treatment)
- Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 24 Weeks of Treatment(after 24 weeks of treatment)
- Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 52 Weeks of Treatment(after 52 weeks of treatment)
- Body Weight After 24 Weeks of Treatment(after 24 weeks of treatment)
- Body Weight After 52 Weeks of Treatment(after 52 weeks of treatment)
- Hypoglycaemic Episodes(over 52 weeks of treatment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00154414Novo Nordisk A/S226
已完成
3 期
Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00395746Novo Nordisk A/S264
已完成
2 期
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00154401Novo Nordisk A/S177
已完成
3 期
Liraglutide in Adolescents With Type 1 DiabetesType 1 DiabetesNCT02516657University at Buffalo5
已完成
3 期
Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00614120Novo Nordisk A/S929